Pd-1/tigit binding proteins for cancer treatment
AssigneeMedImmune, LLC
InventorsMoritz DRACHSLER, KyoungSoo LIM, Chang GONG
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods of treating cancer by administering binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”) to a subject in an amount from about 70 mg to about 1500 mg.
Claims31
A method for treating cancer in a subject, comprising administering to the subject a bispecific binding protein that specifically binds to Programed Death-1 (PD-1) and T cell immunoreceptor with Ig and ITIM domain (TIGIT) in an amount from about 70 mg to about 1500 mg, the bispecific binding protein comprising:
- a) a first binding domain that specifically binds to PD-1, wherein the first binding domain comprises a heavy chain variable domain comprising a HCDR1 having the amino acid sequence of SEQ ID NO:
- 1, a HCDR2 having the amino acid sequence of SEQ ID NO:
- 2, and a HCDR3 having the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable domain comprising a LCDR1 having the amino acid sequence of SEQ ID NO:
- 4, a LCDR2 having the amino acid sequence of SEQ ID NO:
- 5 and a LCDR3 having the amino acid sequence of SEQ ID NO:
- 6;
- and
- b) a second binding domain that specifically binds to TIGIT, wherein the second binding domain comprises a heavy chain variable domain comprising a HCDR1 having the amino acid sequence of SEQ ID NO:
- 11, a HCDR2 having the amino acid sequence of SEQ ID NO:
- 12, and a HCDR3 having the amino acid sequence of SEQ ID NO:
- 13, and a light chain variable domain comprising a LCDR1 having the amino acid sequence of SEQ ID NO:
- 14, a LCDR2 having the amino acid sequence of SEQ ID NO:
- 15, and a LCDR3 having the amino acid sequence of SEQ ID NO:
- 16.
2-4. (canceled)
6-14. (canceled)
16-22. (canceled)
30-31. (canceled)
(canceled)
35-37. (canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising a bispecific binding protein that specifically binds to PD-1 and TIGIT in an amount from about 70 mg to about 1500 mg, the bispecific binding protein comprising:
- a) a first binding domain that specifically binds to PD-1, wherein the first binding domain comprises a heavy chain variable domain comprising a HCDR1 having the amino acid sequence of SEQ ID NO:
- 1, a HCDR2 having the amino acid sequence of SEQ ID NO:
- 2, and a HCDR3 having the amino acid sequence of SEQ ID NO:
- 3, and a light chain variable domain comprising a LCDR1 having the amino acid sequence of SEQ ID NO:
- 4, a LCDR2 having the amino acid sequence of SEQ ID NO:
- 5 and a LCDR3 having the amino acid sequence of SEQ ID NO:
- 6;
- and
- b) a second binding domain that specifically binds to TIGIT, wherein the second binding domain comprises a heavy chain variable domain comprising a HCDR1 having the amino acid sequence of SEQ ID NO:
- 11, a HCDR2 having the amino acid sequence of SEQ ID NO:
- 12, and a HCDR3 having the amino acid sequence of SEQ ID NO:
- 13, and a light chain variable domain comprising a LCDR1 having the amino acid sequence of SEQ ID NO:
- 14, a LCDR2 having the amino acid sequence of SEQ ID NO:
- 15, and a LCDR3 having the amino acid sequence of SEQ ID NO:
- 16.
(canceled)
48-55. (canceled)
57-64. (canceled)
Dependencies are inferred from the claim text.